Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment.

Tian Qian,Xia Jiang,Daojun Zhang,Yao Song,Fei Hao

Expert opinion on drug safety（2023）

引用 0|浏览4

暂无评分

摘要

Regarding risk-benefit assessment, OMA 300 mg emerges as the optimal pharmacological intervention for CU, while OMA 150 mg stands as a secondary alternative compared to H1 antihistamines and cyclosporine.

查看译文

关键词

Chronic urticaria, network meta-analysis, risk-benefit assessment, drug therapy, treatment effectiveness, H1 antihistamine, omalizumab, cyclosporine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要